Bank of America
SYRE icon

Bank of America’s Spyre Therapeutics SYRE Stock Holding History

Bank of America’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.9M Buy
1,228,093
+808,366
+193% +$30.5M ﹤0.01% 1458
2025
Q4 		$13.8M Buy
419,727
+74,924
+22% +$1.96M ﹤0.01% 2594
2025
Q3 		$5.78M Sell
344,803
-51,548
-13% -$841K ﹤0.01% 3850
2025
Q2 		$5.93M Sell
396,351
-30,724
-7% -$455K ﹤0.01% 3719
2025
Q1 		$6.89M Buy
427,075
+419,933
+5,880% +$8.74M ﹤0.01% 3497
2024
Q4 		$166K Sell
7,142
-250,655
-97% -$7.35M ﹤0.01% 6193
2024
Q3 		$7.58M Buy
257,797
+66,628
+35% +$1.86M ﹤0.01% 3342
2024
Q2 		$4.49M Buy
191,169
+154,837
+426% +$5.22M ﹤0.01% 3710
2024
Q1 		$1.38M Buy
+36,332
New +$1.05M ﹤0.01% 4718
2023
Q2 		– Sell
-1,409
Closed -$10.2K – 7939
2023
Q1 		$10.2K Buy
1,409
+778
+123% +$8.54K ﹤0.01% 6911
2022
Q4 		$7.08K Buy
631
+164
+35% +$2.95K ﹤0.01% 6992
2022
Q3 		$6K Buy
467
+175
+60% +$2.16K ﹤0.01% 7358
2022
Q2 		$4K Sell
292
-428
-59% -$15K ﹤0.01% 7658
2022
Q1 		$41K Sell
720
-523
-42% -$43.9K ﹤0.01% 7253
2021
Q4 		$147K Buy
1,243
+217
+21% +$34.2K ﹤0.01% 6672
2021
Q3 		$204K Buy
1,026
+217
+27% +$38K ﹤0.01% 6299
2021
Q2 		$141K Sell
809
-779
-49% -$142K ﹤0.01% 6309
2021
Q1 		$314K Buy
1,588
+1,047
+194% +$201K ﹤0.01% 5719
2020
Q4 		$106K Sell
541
-1,439
-73% -$298K ﹤0.01% 5956
2020
Q3 		$351K Buy
1,980
+1,207
+156% +$223K ﹤0.01% 4962
2020
Q2 		$179K Buy
773
+236
+44% +$44.9K ﹤0.01% 5323
2020
Q1 		$63K Sell
537
-465
-46% -$79.1K ﹤0.01% 5769
2019
Q4 		$191K Sell
1,002
-113
-10% -$22.2K ﹤0.01% 5667
2019
Q3 		$214K Buy
1,115
+55
+5% +$10.7K ﹤0.01% 5629
2019
Q2 		$182K Buy
1,060
+512
+93% +$88.5K ﹤0.01% 5691
2019
Q1 		$111K Sell
548
-138
-20% -$28.8K ﹤0.01% 5828
2018
Q4 		$128K Buy
686
+515
+301% +$109K ﹤0.01% 5786
2018
Q3 		$41K Buy
171
+56
+49% +$13.1K ﹤0.01% 6290
2018
Q2 		$31K Sell
115
-183
-61% -$45K ﹤0.01% 6352
2018
Q1 		$74K Buy
298
+18
+6% +$3.25K ﹤0.01% 5885
2017
Q4 		$38K Hold
280
– – ﹤0.01% 6186
2017
Q3 		$35K Buy
+280
New +$26.2K ﹤0.01% 6087
2016
Q4 		– Sell
-18
Closed -$3K – 7298
2016
Q3 		$3K Sell
18
-16
-47% -$2.23K ﹤0.01% 6742
2016
Q2 		$4K Buy
+34
New +$6.52K ﹤0.01% 6742

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Bank of America's SYRE Position: Q1 2026 in Review

Bank of America increased its Spyre Therapeutics (SYRE) stake by 193% in Q1 2026, buying an estimated $30.5M and bringing the position to 1,228,093 shares worth $61.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1458.

Bank of America first reported a position in SYRE in Q2 2016 and has held it in 34 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Bank of America held 1,228,093 shares of Spyre Therapeutics worth $61.9M as of Q1 2026.
  • Bank of America bought 808,366 Spyre Therapeutics shares in Q1 2026, an estimated $30.5M.
  • Spyre Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1458 holding.
  • Bank of America first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 34 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.